Table 3.

Efficacy of amoxicillin-clavulanate at doses resulting in levels in rat serum simulating levels in human serum obtained following oral administration of either 500/125 mg t.i.d. or 875/125 mg b.i.d. against a respiratory tract infection caused by strains ofS. pneumoniae with different susceptibilities

StrainBacteriological counts (mean ± SD log10CFU/pair of lungs)
Amoxicillin-clavulanate (500/125 mg t.i.d.)Amoxicillin-clavulanate (875/125 mg b.i.d.)Untreated controls
13202.71 ± 1.43a2.48 ± 0.86a7.07 ± 0.24
APS13.42 ± 0.93a2.88 ± 0.99a6.73 ± 0.67
N13873.78 ± 1.05a3.61 ± 1.01a6.74 ± 0.32
143196.01 ± 0.524.95 ± 0.58b6.61 ± 0.49
  • a Significantly different from untreated controls (P < 0.01).

  • b Significantly different from results for untreated controls and animals treated with amoxicillin-clavulanate at a dose resulting in levels of 500/125 mg in humans (P < 0.01).